AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26552022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-based chemotherapy
Number of subjects: 86
Study 26552022 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 86
Study 23855318 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone + Face-to-Face
Number of subjects: 58
Study 23855318 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-Face Only
Number of subjects: 58
Study 23855318 — intervention group
Group type: COMPARATOR
Intervention: Both programs
Number of subjects: 58
Study 20597629 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred self-care intervention (CCSCI)
Number of subjects: 40
Study 20597629 — intervention group
Group type: COMPARATOR
Intervention: Ordinary training (Control)
Number of subjects: 40
Study 20597629 — intervention group
Group type: COMPARATOR
Intervention: Both groups (IG and CG)
Number of subjects: 40
Study 18454042 — intervention group
Group type: EXPERIMENTAL
Intervention: Wetting alarm diaper training (WAD-T)
Number of subjects: 39
Study 18454042 — intervention group
Group type: COMPARATOR
Intervention: Timed potty training (TP-T)
Number of subjects: 39
Study 16571280 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus Injection (AI) 20 ml in 250 ml of 5% glucose solution given through intravenous dripping
Number of subjects: 63
Study 16571280 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 63
Study 14577838 — intervention group
Group type: COMPARATOR
Intervention: Dawn simulator devices used for two weeks at a time during an eight-week study period.
Number of subjects: 100
Study 12775739 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1049
Study 12775739 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (after crossover)
Number of subjects: 1049
Study 12775739 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa plus low-dose cytarabine (IFN+LDAC)
Number of subjects: 1049
Study 10367553 — intervention group
Group type: COMPARATOR
Intervention: MDMA (1.7 mg/kg, orally) in humans
Number of subjects: 0
Study 10367553 — intervention group
Group type: COMPARATOR
Intervention: MDMA (1.7, 5.4, and 17.0 mg/kg) in rats
Number of subjects: 0
Study 10367553 — intervention group
Group type: COMPARATOR
Intervention: Placebo in humans
Number of subjects: 0
Study 10367553 — intervention group
Group type: COMPARATOR
Intervention: Placebo in rats
Number of subjects: 0
Study 8904739 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone 2.5 mg
Number of subjects: 12
Study 8904739 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone 10 mg
Number of subjects: 12
Study 8904739 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone 20 mg
Number of subjects: 12
Study 8904739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1653145 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release tablets (30 mg every 12 h)
Number of subjects: 11
Study 1653145 — intervention group
Group type: COMPARATOR
Intervention: Solution (15 mg every 6 h)
Number of subjects: 11
Study 6363696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 0
Study 6363696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30064268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of physical exercise and cognitive training (n=55; 50-minute session + 60-minute session)
Number of subjects: 225
Study 30064268 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (n=56; 50-minute session)
Number of subjects: 225
Study 30064268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (n=57; 60-minute session)
Number of subjects: 225
Study 30064268 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=57; 45-minute session)
Number of subjects: 225
Study 30368448 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (BF) Spiromax
Number of subjects: 1476
Study 30368448 — intervention group
Group type: COMPARATOR
Intervention: BF Turbuhaler
Number of subjects: 1476
Study 27434297 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Nilotinib
Number of subjects: 12
Study 27434297 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Nilotinib
Number of subjects: 12
Study 27434297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (both doses)
Number of subjects: 12
Study 24579935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (1 × 10^8 CFU for 5 days)
Number of subjects: 127
Study 24579935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 127
Study 24579935 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 23319889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 90
Study 23319889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 90
Study 20965978 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C reactive protein (hsCRP)
Number of subjects: 382
Study 20965978 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 382
Study 20965978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentraxin-3 (PTX3)
Number of subjects: 382
Study 20965978 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent AF
Number of subjects: 382
Study 17690742 — intervention group
Group type: EXPERIMENTAL
Intervention: FEXOFENADINE 180 mg Film Tablet (Drogsan A.S., Ankara, Turkey)
Number of subjects: 25
Study 17690742 — intervention group
Group type: COMPARATOR
Intervention: Telfast 180 mg Tablet (Aventis Pharma, Frankfurt am Main, Germany)
Number of subjects: 25
Study 15361515 — intervention group
Group type: EXPERIMENTAL
Intervention: RMSdi measured during steady-state ventilation at seven levels of inspired O2 fraction (Fi(CO(2))) from 0 to 0.08
Number of subjects: 7
Study 15361515 — intervention group
Group type: EXPERIMENTAL
Intervention: RMSdi%max-Pco(2) relationships
Number of subjects: 7
Study 15361515 — intervention group
Group type: EXPERIMENTAL
Intervention: RMSdi/ECG(R)-Pco(2) relationships
Number of subjects: 7
Study 11916788 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean hand acupressure (performed 30 min before anesthesia using acupressure seeds on K-K9 for at least 24 h)
Number of subjects: 80
Study 11916788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no active acupressure)
Number of subjects: 80
Study 9537342 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 104
Study 9537342 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 104
Study 7702022 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine with low concentration of polyphenols
Number of subjects: 33
Study 7702022 — intervention group
Group type: COMPARATOR
Intervention: Red wine with high concentration of polyphenols
Number of subjects: 33
Study 7702022 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine with reduced alcohol content
Number of subjects: 33
Study 7702022 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine with reduced alcohol content consumed with food (small bread roll)
Number of subjects: 33
Study 7702022 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine with reduced alcohol content
Number of subjects: 33
Study 2676312 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed every 4 hours (62 infants)
Number of subjects: 152
Study 2676312 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed every 3 hours (90 infants)
Number of subjects: 152
Study 40893 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic norgestrel/ethinyl estradiol regimen
Number of subjects: 458
Study 40893 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic norgestrel/ethinyl estradiol regimen
Number of subjects: 458
Study 40893 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose norgestrel/ethinyl estradiol preparation (300 mcg norgestrel and 30 mcg ee)
Number of subjects: 458
Study 31168676 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed scaffolds
Number of subjects: 0
Study 31168676 — intervention group
Group type: COMPARATOR
Intervention: Naphthalene scaffolds (traditional processing)
Number of subjects: 0
Study 29659183 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravitreal aflibercept (IVT‐AFL) injection every 4 weeks (0.5q4)
Number of subjects: 1815
Study 29659183 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg IVT‐AFL every 4 weeks (2q4)
Number of subjects: 1815
Study 29659183 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg IVT‐AFL every 8 weeks (2q8)
Number of subjects: 1815
Study 29659183 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg intravitreal ranibizumab every 4 weeks (0.5q4)
Number of subjects: 1815
Study 29659183 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (IVT‐AFL and ranibizumab)
Number of subjects: 1815
Study 29126422 — intervention group
Group type: EXPERIMENTAL
Intervention: CHMI-a and CHMI-b (exposure to infected mosquitoes)
Number of subjects: 39
Study 25298028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic activity of MRSA isolates
Number of subjects: 386
Study 25298028 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cytotoxicity MRSA isolates
Number of subjects: 386
Study 25298028 — intervention group
Group type: EXPERIMENTAL
Intervention: Clone with low cytotoxic activity
Number of subjects: 386
Study 24204066 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 410
Study 21767415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 93
Study 21767415 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 93
Study 21767415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SP and Mefloquine
Number of subjects: 93
Study 18091548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G 10% (ivIgG) - 6 mL [600 mg]/kg on day 1 and 3 mL [300 mg]/kg on day 2
Number of subjects: 244
Study 18091548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin 0.1%) - 6 mL [6 mg]/kg on day 1 and 3 mL [3 mg]/kg on day 2
Number of subjects: 244
Study 18091548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G 10% (ivIgG)
Number of subjects: 244
Study 18091548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin 0.1%)
Number of subjects: 244
Study 16935946 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administered cognitive behaviour therapy (CBT)
Number of subjects: 72
Study 16935946 — intervention group
Group type: COMPARATOR
Intervention: Face to face cognitive behaviour therapy (CBT)
Number of subjects: 72
Study 12971668 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based directly observed treatment (FDOT)
Number of subjects: 173
Study 12971668 — intervention group
Group type: COMPARATOR
Intervention: Standard supervised but non-observed therapy (ST)
Number of subjects: 173
Study 11425414 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (abstinence)
Number of subjects: 100
Study 11425414 — intervention group
Group type: COMPARATOR
Intervention: Smoking (continuation)
Number of subjects: 100
Study 9237141 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial denture with distal occlusal rests and cast circumferential clasps
Number of subjects: 118
Study 9237141 — intervention group
Group type: COMPARATOR
Intervention: Partial denture with mesial rests and I-bar cast clasps
Number of subjects: 118
Study 7525999 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneuploid DNA profiles in interstitial cystitis patients (n=14)
Number of subjects: 14
Study 7525999 — intervention group
Group type: COMPARATOR
Intervention: Aneuploid DNA profiles in control patients (n=11)
Number of subjects: 14
Study 7525999 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA tetraploid population in interstitial cystitis patients (n=14)
Number of subjects: 14
Study 7525999 — intervention group
Group type: COMPARATOR
Intervention: DNA tetraploid population in control patients (n=11)
Number of subjects: 14
Study 7525999 — intervention group
Group type: EXPERIMENTAL
Intervention: Binucleated cytokeratin positive cells in interstitial cystitis patients
Number of subjects: 14
Study 7525999 — intervention group
Group type: COMPARATOR
Intervention: Binucleated cytokeratin positive cells in control patients
Number of subjects: 14
Study 3302841 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride 150 mg/day
Number of subjects: 0
Study 3302841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2190839 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg tamoxifen/day
Number of subjects: 67
Study 2190839 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg tamoxifen/day and 600 IU kallikrein/day
Number of subjects: 67
Study 4494855 — intervention group
Group type: EXPERIMENTAL
Intervention: Description of only 2 of the sensations the subjects could expect to experience
Number of subjects: 52
Study 4494855 — intervention group
Group type: EXPERIMENTAL
Intervention: Description of all the typical sensations experienced
Number of subjects: 52
Study 4494855 — intervention group
Group type: COMPARATOR
Intervention: Description of sensations unlikely to occur with ischemic pain
Number of subjects: 52
Study 4494855 — intervention group
Group type: COMPARATOR
Intervention: Description of the procedure void of sensations
Number of subjects: 52
Study 31520695 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy followed by resectability assessment by the Expert Panel
Number of subjects: 183
Study 31520695 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative procedures performed on patients with resectable CRLM
Number of subjects: 183
Study 28024275 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress induction during memory reactivation
Number of subjects: 0
Study 28024275 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no reactivation, no stress, or both)
Number of subjects: 0
Study 25896460 — intervention group
Group type: EXPERIMENTAL
Intervention: Choroidal thickness measurements at various locations (fovea, N750, N1500, N2250, T750, T1500, T2250)
Number of subjects: 294
Study 23443875 — intervention group
Group type: COMPARATOR
Intervention: Oral paracetamol (1,000 mg)
Number of subjects: 45
Study 23443875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injection
Number of subjects: 45
Study 22436512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness in left ventromedial and right dorsolateral prefrontal cortices
Number of subjects: 105
Study 22436512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness in left inferior frontal, left cingulate, and right dorsomedial prefrontal cortices
Number of subjects: 105
Study 22436512 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter volume in right frontal white matter
Number of subjects: 105
Study 19849857 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-appropriate hypertension education (three sessions, culturally-specific materials, targeted lifestyle support)
Number of subjects: 148
Study 19849857 — intervention group
Group type: COMPARATOR
Intervention: Standard hypertension education (usual care)
Number of subjects: 148
Study 17823436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index (LGI) diet
Number of subjects: 203
Study 17823436 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic-index (HGI) diet
Number of subjects: 203
Study 14679399 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MU of IFN-beta twice a day at intervals of 5 and 19 h (Group A)
Number of subjects: 9
Study 14679399 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MU of IFN-beta twice a day at intervals of 10 and 14 h (Group B)
Number of subjects: 9
Study 14679399 — intervention group
Group type: COMPARATOR
Intervention: 6MU of IFN-alpha once a day with ribavirin (Group C)
Number of subjects: 9
Study 10655829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential single pumping regimen
Number of subjects: 39
Study 10655829 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous double pumping regimen
Number of subjects: 39
Study 10655829 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous breastfeeding experience
Number of subjects: 39
Study 10655829 — intervention group
Group type: COMPARATOR
Intervention: No previous breastfeeding experience
Number of subjects: 39
Study 8909755 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone net dressing (Mepitel)
Number of subjects: 38
Study 8909755 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze dressing
Number of subjects: 38
Study 2069370 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin (6 mg/kg/day) given once daily (qd)
Number of subjects: 60
Study 2069370 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin (6 mg/kg/day) given thrice daily (tid)
Number of subjects: 60
Study 6347782 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg three times a day for 4-6 weeks
Number of subjects: 14
Study 6347782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6347782 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 14
Study 31041545 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue thiopurines (Con) group
Number of subjects: 50
Study 31041545 — intervention group
Group type: COMPARATOR
Intervention: Discontinue thiopurines (Dis) group
Number of subjects: 50
Study 28768217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 333
Study 28768217 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 333
Study 25516113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (MBT)
Number of subjects: 103
Study 25516113 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual treatment)
Number of subjects: 103
Study 23403431 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 (100, 200, 400, 800, 1500 mg; 800 mg with high-fat meal)
Number of subjects: 39
Study 23403431 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 (800 mg with high-fat meal)
Number of subjects: 39
Study 23403431 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322
Number of subjects: 39
Study 23403431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 21592898 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 21592898 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 19754931 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary melon juice concentrate (Extramel) 10 mg corresponding to 140 IU SOD per capsule, taken once daily for 4 weeks
Number of subjects: 70
Study 19754931 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken once daily for 4 weeks
Number of subjects: 70
Study 16775183 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobook intervention provided immediately (n = 49)
Number of subjects: 100
Study 16775183 — intervention group
Group type: COMPARATOR
Intervention: Photobook intervention provided 4 months after initial intervention delivery (n = 51)
Number of subjects: 100
Study 15022020 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade fishing line suture
Number of subjects: 220
Study 15022020 — intervention group
Group type: COMPARATOR
Intervention: Commercial nylon thread (Ethilon)
Number of subjects: 220
Study 10659979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (900 mg/day)
Number of subjects: 0
Study 10659979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9107002 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat exposure with an affiliate facing the same situation
Number of subjects: 2
Study 9107002 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat exposure with an affiliate facing a different situation
Number of subjects: 2
Study 9107002 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threat exposure with an affiliate facing the same situation
Number of subjects: 2
Study 9107002 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threat exposure with an affiliate facing a different situation
Number of subjects: 2
Study 9107002 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral mimicry (facial expressions)
Number of subjects: 2
Study 9107002 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional contagion (self-reported anxiety)
Number of subjects: 2
Study 1389351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt Lightening Gel and Whitening Toothpaste
Number of subjects: 0
Study 1389351 — intervention group
Group type: COMPARATOR
Intervention: Rembrandt Toothpaste alone
Number of subjects: 0
Study 1389351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching system
Number of subjects: 0
Study 3905327 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso Mack Retard 20 mg
Number of subjects: 8
Study 3905327 — intervention group
Group type: EXPERIMENTAL
Intervention: Two development products
Number of subjects: 8
Study 3905327 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoket Retard 20 mg
Number of subjects: 8
Study 3905327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release preparations
Number of subjects: 8
Study 3905327 — intervention group
Group type: COMPARATOR
Intervention: Isoket retard 20 mg
Number of subjects: 8
Study 3905327 — intervention group
Group type: COMPARATOR
Intervention: IS‐5‐MN non-retard
Number of subjects: 8
Study 31481370 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Aware of Mental Health (YAM)
Number of subjects: 8600
Study 31481370 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health and High School Curriculum Guide (The Guide)
Number of subjects: 8600
Study 31481370 — intervention group
Group type: COMPARATOR
Intervention: Usual Provision
Number of subjects: 8600
Study 31481370 — intervention group
Group type: EXPERIMENTAL
Intervention: YAM and The Guide
Number of subjects: 8600
Study 29670335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (120 mg)
Number of subjects: 36
Study 29670335 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg)
Number of subjects: 36
Study 29670335 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of fimasartan and rosuvastatin
Number of subjects: 36